LOFEPRAMINE: 48 Adverse Event Reports & Safety Profile
Sharpen Your Memory & Focus Naturally
NeuroZoom — 35 clinically studied ingredients. No stimulants. Pure brain support.
48
Total FAERS Reports
1 (2.1%)
Deaths Reported
13
Hospitalizations
48
As Primary/Secondary Suspect
6
Life-Threatening
1
Disabilities
First Report: 200104 · Latest Report: 20180307
What Are the Most Common LOFEPRAMINE Side Effects?
#1 Most Reported
Hyponatraemia
14 reports (29.2%)
#2 Most Reported
White blood cell count decreased
8 reports (16.7%)
#3 Most Reported
Tuberculosis of central nervous system
8 reports (16.7%)
All LOFEPRAMINE Side Effects by Frequency
| Side Effect | Reports | % of Total | Deaths | Hosp. |
|---|---|---|---|---|
| Hyponatraemia | 14 | 29.2% | 0 | 3 |
| Antipsychotic drug level above therapeutic | 8 | 16.7% | 0 | 8 |
| Tuberculosis of central nervous system | 8 | 16.7% | 0 | 8 |
| White blood cell count decreased | 8 | 16.7% | 0 | 8 |
| Deafness neurosensory | 7 | 14.6% | 0 | 0 |
| Drug ineffective | 7 | 14.6% | 0 | 0 |
| Foetal exposure during pregnancy | 7 | 14.6% | 0 | 0 |
| Inappropriate antidiuretic hormone secretion | 7 | 14.6% | 0 | 0 |
| Labelled drug-drug interaction medication error | 7 | 14.6% | 0 | 7 |
| Vestibular disorder | 7 | 14.6% | 0 | 0 |
| Depression | 6 | 12.5% | 0 | 0 |
| Respiratory depression | 6 | 12.5% | 0 | 0 |
| Anxiety | 5 | 10.4% | 0 | 0 |
Who Reports LOFEPRAMINE Side Effects? Age & Gender Data
Gender: 56.5% female, 43.5% male. Average age: 54.1 years. Most reports from: GB. View detailed demographics →
Is LOFEPRAMINE Getting Safer? Reports by Year
| Year | Reports | Deaths | Hosp. |
|---|---|---|---|
| 2001 | 1 | 0 | 0 |
| 2002 | 1 | 0 | 0 |
| 2008 | 1 | 0 | 0 |
| 2013 | 1 | 0 | 0 |
| 2014 | 5 | 0 | 2 |
| 2016 | 8 | 0 | 8 |
| 2018 | 3 | 0 | 3 |
What Is LOFEPRAMINE Used For?
| Indication | Reports |
|---|---|
| Depression | 18 |
| Anxiety | 8 |
| Tuberculosis of central nervous system | 7 |
| Product used for unknown indication | 5 |
Official FDA Label for LOFEPRAMINE
Official prescribing information from the FDA-approved drug label.